Regeneron Pharmaceuticals (REGN) Times Interest Earned (2009 - 2026)

Regeneron Pharmaceuticals' Times Interest Earned history runs 18 years deep, the most recent figure standing at $22.72 for Q1 2026.

• On a quarterly basis, Times Interest Earned fell 32.04% year-over-year to $22.72 in Q1 2026; TTM through Mar 2026 was $128.24, a 40.75% decrease from a year earlier, with the FY2025 full-year figure at $28.85, up 359.41% from the prior year.
• Times Interest Earned advanced to $22.72 in Q1 2026 per REGN's latest filing, from $13.73 in the prior quarter.
• Across five years, Times Interest Earned topped out at $105.83 in Q2 2025 and bottomed at $3.53 in Q3 2022.
• The 5-year median for Times Interest Earned is $13.73 (2025), against an average of $27.05.
• Across the five-year window, Times Interest Earned sank 98.31% in 2022 and surged 814.66% in 2024, its largest moves.
• Year by year, Times Interest Earned stood at $65.91 in 2022, then declined by 19.77% to $52.88 in 2023, then tumbled by 58.84% to $21.76 in 2024, then sank by 36.92% to $13.73 in 2025, then jumped by 65.49% to $22.72 in 2026.
• Per Business Quant, the three latest REGN Times Interest Earned figures stand at $22.72 (Q1 2026), $13.73 (Q4 2025), and $53.2 (Q3 2025).